Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01F
- Chemical subgroupL01FXOther monoclonal antibodies and antibody drug conjugates
- Chemical substanceL01FX07Blinatumomab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Brazil
Anvisa · 1 registration
Canada
Health Canada · 1 registration
Spain
AEMPS · 1 registration
European Union
EMA · 1 registration
At a glance
- ATC code
- L01FX07
- Registers
- 8
- Historical lists
- 2
- Registrations
- 10
- With their own page
- 8
- Companies
- 6
All medicines with Blinatumomab
Human medicines from every register that match Blinatumomab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
10 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Blincyto | United States | 35MCG | injectable | Marketed | Amgen |
| Blincyto | European Union | Authorised | Amgen Europe B.V. | ||
| Blincyto | Canada | 38.5 MCG / VIAL | Powder For Solution | Marketed | Amgen Canada INC |
| Blincyto | Brazil | Authorised | Amgen Biotecnologia do Brasil Ltda. | ||
| Blincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusion | Spain | 38,5 µg | polvo para concentrado y solución para solución para perfusion | Marketed | Amgen Europe B.V. |
| Blincyto | Croatia | Marketed | |||
| Blincyto 12.5 mcg/mL poeder voor concentraat voor oplossing voor infusie | Netherlands | Poeder voor concentraat voor oplossing voor infusie | Authorised | Amgen Europe B.V. | |
| Blincyto Powder for Infusion 35 MCG/Vial | Singapore | 55.0 μg/mL | injection, powder, lyophilized, for solution | Authorised | Amgen Biotechnology Singapore Pte LTD |
| Blincyto | Saudi Arabia | Authorised | Boehringer Ingelheim Pharma GmbH & Co. KG | ||
| BLINCYTO 38,5 micrograme | Romania | 38,5micrograme | pulb. pt. conc. si sol. pt. sol. perf. | Status unknown | Amgen Europe B.V. |